KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Income from Continuing Operations (2016 - 2026)

NovoCure's Income from Continuing Operations history spans 13 years, with the latest figure at 71138000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 107.28% to 71138000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 173046000.0, a 5.4% decrease, with the full-year FY2025 number at 136227000.0, up 19.21% from a year prior.
  • Income from Continuing Operations hit 71138000.0 in Q1 2026 for NovoCure, down from 24499000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for NVCR hit a ceiling of 4647000.0 in Q1 2022 and a floor of 71138000.0 in Q1 2026.
  • Historically, Income from Continuing Operations has averaged 39739352.94 across 5 years, with a median of 37303000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 1041.83% in 2023 and later surged 62.84% in 2025.
  • Tracing NVCR's Income from Continuing Operations over 5 years: stood at 37303000.0 in 2022, then decreased by 26.21% to 47079000.0 in 2023, then plummeted by 40.02% to 65922000.0 in 2024, then surged by 62.84% to 24499000.0 in 2025, then tumbled by 190.37% to 71138000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for NVCR at 71138000.0 in Q1 2026, 24499000.0 in Q4 2025, and 37270000.0 in Q3 2025.